{"reference_clinvar_assertion": {"clinvar_accession": {"acc": "RCV000022525", "version": 25, "type": "RCV", "date_updated": "2022-04-23", "date_created": "2013-04-04"}, "record_status": "current", "clinical_significance": {"review_status": "no assertion criteria provided", "description": "pathogenic", "date_last_evaluated": "2011-02-11"}, "assertion": "variation to disease", "observed_in": [{"sample": {"origin": "germline", "species": {"value": "human", "taxonomy_id": 9606}, "affected_status": "not provided", "number_tested": 1}, "methods": ["literature only", "literature only"], "observed_data": [{"attribute": {"type": "Description", "value": "In 3 affected sibs, born of distantly related parents of European descent, with megaloblastic anemia due to dihydrofolate reductase deficiency (613839), Cario et al. (2011) identified a homozygous 458A-T transversion in exon 5 of the DHFR gene, resulting in an asp153-to-val (D153V) substitution. Both parents were heterozygous for the D153V mutation, which was not found in 120 control samples. The mutation was predicted to interrupt hydrogen bonding, affecting fold and conformational stability, resulting in decreased enzyme activity. Studies of patient lymphoblastoid cells showed that DHFR activity was reduced to about 10% of control levels. DHFR expression was similar to controls, but protein levels were severely decreased. Although 1 sib was essentially unaffected except for macrocytosis, the other 2 sibs developed childhood absence epilepsy with eyelid myoclonia in childhood. One had learning disabilities. Levels of 5-methyltetrahydrofolate (5-MTHF) in the CSF were low, but improved with folinic acid treatment."}, "citations": [{"ids": [{"source": "PubMed", "value": "21310277"}], "type": "general"}]}, {"attribute": {"type": "Description", "value": "not provided"}}]}], "measure_set": {"type": "Variant", "acc": "VCV000029674", "version": 1, "measures": [{"names": [{"value": {"type": "Preferred", "value": "NM_000791.4(DHFR):c.458A>T (p.Asp153Val)"}}, {"value": {"type": "Alternate", "value": "DHFRc.458A>T"}}, {"value": {"type": "Alternate", "value": "DHFRp.D153V"}}, {"value": {"type": "Alternate", "value": "DHFRp.Asp153Val"}}], "canonical_spdi": "NC_000005.10:80633903:T:A", "attributes": [{"type": "HGVS, coding, RefSeq", "value": "NM_001290354.2:c.302A>T"}, {"type": "HGVS, coding, RefSeq", "value": "NM_001290357.2:c.369+3979A>T"}, {"type": "HGVS, coding, RefSeq", "value": "NM_000791.4:c.458A>T"}, {"type": "HGVS, genomic, RefSeqGene", "value": "NG_023304.1:g.26078A>T"}, {"type": "HGVS, genomic, top level", "value": "NC_000005.10:g.80633904T>A"}, {"type": "HGVS, genomic, top level, previous", "value": "NC_000005.9:g.79929723T>A"}, {"type": "HGVS, non-coding", "value": "NR_110936.2:n.775A>T"}, {"type": "HGVS, previous", "value": "NM_000791.3:c.458A>T"}, {"type": "HGVS, protein", "value": "P00374:p.Asp153Val"}, {"type": "HGVS, protein, RefSeq", "value": "NP_001277283.1:p.Asp101Val"}, {"type": "HGVS, protein, RefSeq", "value": "NP_000782.1:p.Asp153Val"}, {"type": "MolecularConsequence", "value": "intron variant", "xrefs": [{"db": "Sequence Ontology", "id": "SO:0001627"}, {"db": "RefSeq", "id": "NM_001290357.2:c.369+3979A>T"}]}, {"type": "MolecularConsequence", "value": "missense variant", "xrefs": [{"db": "Sequence Ontology", "id": "SO:0001583"}, {"db": "RefSeq", "id": "NM_000791.4:c.458A>T"}]}, {"type": "MolecularConsequence", "value": "missense variant", "xrefs": [{"db": "Sequence Ontology", "id": "SO:0001583"}, {"db": "RefSeq", "id": "NM_001290354.2:c.302A>T"}]}, {"type": "MolecularConsequence", "value": "non-coding transcript variant", "xrefs": [{"db": "Sequence Ontology", "id": "SO:0001619"}, {"db": "RefSeq", "id": "NR_110936.2:n.775A>T"}]}, {"type": "ProteinChange1LetterCode", "value": "D101V"}, {"type": "ProteinChange1LetterCode", "value": "D153V"}, {"type": "ProteinChange3LetterCode", "value": "ASP153VAL"}], "sequence_location": [{"assembly": "GRCh38", "chr": "5", "accession": "NC_000005.10", "start": 80633904, "stop": 80633904, "display_start": 80633904, "display_stop": 80633904, "variant_length": 1, "assembly_accesion_version": "GCF_000001405.38", "assembly_status": "current", "position_vcf": 80633904, "reference_allele_vcf": "T", "alternate_allele_vcf": "A"}, {"assembly": "GRCh37", "chr": "5", "accession": "NC_000005.9", "start": 79929723, "stop": 79929723, "display_start": 79929723, "display_stop": 79929723, "variant_length": 1, "assembly_accesion_version": "GCF_000001405.25", "assembly_status": "previous", "position_vcf": 79929723, "reference_allele_vcf": "T", "alternate_allele_vcf": "A"}], "measure_relationship": [{"names": [{"value": {"type": "Preferred", "value": "dihydrofolate reductase"}}], "symbols": [{"value": {"type": "Preferred", "value": "DHFR"}}], "sequence_locations": [{"assembly": "GRCh38", "chr": "5", "accession": "NC_000005.10", "start": 80626226, "stop": 80654983, "display_start": 80626226, "display_stop": 80654983, "strand": "-", "assembly_accesion_version": "GCF_000001405.38", "assembly_status": "current"}, {"assembly": "GRCh37", "chr": "5", "accession": "NC_000005.9", "start": 79922044, "stop": 79950799, "display_start": 79922044, "display_stop": 79950799, "strand": "-", "variant_length": 28756, "assembly_accesion_version": "GCF_000001405.25", "assembly_status": "previous"}], "xrefs": [{"db": "Gene", "id": "1719"}, {"db": "OMIM", "id": "126060", "type": "MIM"}, {"db": "HGNC", "id": "HGNC:2861"}]}], "citations": [{"ids": [{"source": "PubMed", "value": "1060915"}], "type": "general"}, {"ids": [{"source": "PubMed", "value": "1099447"}], "type": "general"}, {"ids": [{"source": "PubMed", "value": "6700662"}], "type": "general"}], "xrefs": [{"db": "UniProtKB", "id": "P00374#VAR_065819"}, {"db": "OMIM", "id": "126060.0002", "type": "Allelic variant"}, {"db": "dbSNP", "id": "121913223", "type": "rs"}]}], "names": [{"value": {"type": "Preferred", "value": "NM_000791.4(DHFR):c.458A>T (p.Asp153Val)"}}], "xrefs": [{"db": "ClinGen", "id": "CA128553"}], "id": 29674}, "trait_set": {"type": "Disease", "traits": [{"type": "Disease", "names": [{"value": {"type": "Preferred", "value": "Constitutional megaloblastic anemia with severe neurologic disease"}, "xrefs": [{"db": "MONDO", "id": "MONDO:0013456"}]}, {"value": {"type": "Alternate", "value": "DHFR DEFICIENCY"}, "xrefs": [{"db": "OMIM", "id": "613839", "type": "MIM"}]}, {"value": {"type": "Alternate", "value": "Megaloblastic anemia due to dihydrofolate reductase deficiency"}, "xrefs": [{"db": "Genetic Alliance", "id": "Megaloblastic+anemia+due+to+dihydrofolate+reductase+deficiency/8802"}]}], "attributes": [{"value": {"type": "public definition", "value": "Dihydrofolate reductase deficiency is an autosomal recessive metabolic disorder characterized by the hematologic findings of megaloblastic anemia and variable neurologic symptoms, ranging from severe developmental delay and generalized seizures in infancy (Banka et al., 2011) to childhood absence epilepsy with learning difficulties to lack of symptoms (Cario et al., 2011). Treatment with folinic acid can ameliorate some of the symptoms."}, "xrefs": [{"db": "OMIM", "id": "613839", "type": "MIM"}]}, {"value": {"type": "GARD id"}, "xrefs": [{"db": "Office of Rare Diseases", "id": "11000"}]}], "xrefs": [{"db": "MONDO", "id": "MONDO:0013456"}, {"db": "MedGen", "id": "C3151205"}, {"db": "Orphanet", "id": "319651"}, {"db": "OMIM", "id": "613839", "type": "MIM"}]}], "id": 7481}, "date_created": "2013-04-04", "date_last_updated": "2022-04-23", "id": 80028}, "record_status": "current", "replaces": ["RCV000114932"], "title": "NM_000791.4(DHFR):c.458A>T (p.Asp153Val) AND Constitutional megaloblastic anemia with severe neurologic disease", "clinvar_assertions": [{"id": 49070, "clinvar_submission_id": {"local_key": "126060.0002_MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY", "submitter": "OMIM", "title": "DHFR, ASP153VAL_MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY", "submitter_date": "2016-08-04"}, "clinvar_accession": {"acc": "SCV000043814", "version": 2, "type": "SCV", "date_updated": "2016-08-22", "date_created": "2013-04-04", "org_id": "3", "org_type": "primary", "org_category": "resource"}, "assertion_type": "variation to disease", "record_status": "current", "clinical_significance": [{"review_status": "no assertion criteria provided", "descriptions": ["pathogenic"], "date_last_evaluated": "2011-02-11"}], "external_ids": [{"db": "OMIM", "id": "126060.0002", "type": "Allelic variant"}], "observed_in": [{"sample": {"origin": "germline", "species": {"value": "human"}, "affected_status": "not provided"}, "methods": ["literature only"], "observed_data": [{"attribute": {"type": "Description", "value": "In 3 affected sibs, born of distantly related parents of European descent, with megaloblastic anemia due to dihydrofolate reductase deficiency (613839), Cario et al. (2011) identified a homozygous 458A-T transversion in exon 5 of the DHFR gene, resulting in an asp153-to-val (D153V) substitution. Both parents were heterozygous for the D153V mutation, which was not found in 120 control samples. The mutation was predicted to interrupt hydrogen bonding, affecting fold and conformational stability, resulting in decreased enzyme activity. Studies of patient lymphoblastoid cells showed that DHFR activity was reduced to about 10% of control levels. DHFR expression was similar to controls, but protein levels were severely decreased. Although 1 sib was essentially unaffected except for macrocytosis, the other 2 sibs developed childhood absence epilepsy with eyelid myoclonia in childhood. One had learning disabilities. Levels of 5-methyltetrahydrofolate (5-MTHF) in the CSF were low, but improved with folinic acid treatment."}, "citations": [{"ids": [{"source": "PubMed", "value": "21310277"}]}], "xrefs": [{"db": "OMIM", "id": "613839", "type": "MIM"}]}]}], "measure_set": {"type": "Variant", "measures": [{"names": [{"value": {"type": "Preferred", "value": "DHFR, ASP153VAL"}}], "attributes": [{"type": "NonHGVS", "value": "ASP153VAL"}], "measure_relationship": [{"symbols": [{"value": {"type": "Preferred", "value": "DHFR"}}]}], "xrefs": [{"db": "OMIM", "id": "126060.0002", "type": "Allelic variant"}]}]}, "trait_set": [{"type": "Disease", "traits": [{"names": [{"value": {"type": "Preferred", "value": "MEGALOBLASTIC ANEMIA DUE TO DIHYDROFOLATE REDUCTASE DEFICIENCY"}}]}]}]}, {"id": 269026, "clinvar_submission_id": {"local_key": "DHFR_001", "submitter": "Clinic of Pediatric and Adolescent Medicine, University Hospital Ulm", "submitter_date": "2010-11-22"}, "clinvar_accession": {"acc": "SCV000148827", "version": 1, "type": "SCV", "date_updated": "2014-04-24", "date_created": "2014-04-24", "org_id": "504838", "org_type": "primary", "org_category": "laboratory"}, "assertion_type": "variation to disease", "record_status": "current", "clinical_significance": [{"review_status": "no assertion criteria provided", "descriptions": ["pathogenic"], "comments": [{"text": "Converted during submission to Pathogenic.", "type": "ConvertedByNCBI"}]}], "observed_in": [{"sample": {"origin": "germline", "species": {"value": "human"}, "affected_status": "not provided", "number_tested": 1}, "methods": ["not provided"], "observed_data": [{"attribute": {"type": "Description", "value": "not provided"}}]}], "measure_set": {"type": "Variant", "measures": [{"names": [{"value": {"type": "Alternate", "value": "DHFR c.458A>T"}}, {"value": {"type": "Alternate", "value": "DHFR p.D153V"}}, {"value": {"type": "Alternate", "value": "DHFR p.Asp153Val"}}], "attributes": [{"type": "HGVS", "value": "NM_000791.3:c.458A>T"}], "citations": [{"ids": [{"source": "PubMed", "value": "1060915"}], "type": "general"}, {"ids": [{"source": "PubMed", "value": "1099447"}], "type": "general"}, {"ids": [{"source": "PubMed", "value": "6700662"}], "type": "general"}]}]}, "trait_set": [{"type": "Disease", "traits": [{"names": [{"value": {"type": "Preferred", "value": "not provided"}}], "xrefs": [{"db": "OMIM", "id": "126060", "type": "MIM", "status": "under review"}]}]}], "comments": [{"text": "dihydrofolate reductase (DHFR) deficiency. Causes macrocytic anemia and neurologic disease (atypical childhood absence epilepsy);variable phenotypic expression;treatment with follinic acid leads to normal blood counts and improvement of neurologic symptoms. Manuscript submitted for publication, therefore public release of this dbSNP submission only from the time of publication.", "type": "public"}, {"text": "Causes macrocytic anemia and neurologic disease (atypical childhood absence epilepsy);variable phenotypic expression; treatment with follinic acid leads to normal blood counts and improvement of neurologic symptoms.", "type": "public", "datasource": "CuratedByNCBI"}]}]}
